Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying - Preclinical evidence

Journal of Diabetes and its Complications

Volumn 28, Issue 1, 2014, Pages 110-114

  Werner, Ulrich ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Gastric emptying; GLP 1 receptor agonists; Lixisenatide; Postprandial glucose; Type 2 diabetes mellitus

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LIXISENATIDE; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE BLOOD LEVEL; PEPTIDE; ZP10A PEPTIDE;

BINDING AFFINITY; DRUG ABSORPTION; DRUG EFFICACY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH EMPTYING; TACHYPHYLAXIS; VAGUS NERVE; AGONISTS; ANIMAL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GASTRIC EMPTYING; HUMANS; PEPTIDES; POSTPRANDIAL PERIOD; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 84891827870     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2013.06.003     Document Type: Review

References (43)

1. B. Ahrén, A.L. Dimas, P. Miossec, S. Saubadu, and R. Aronson Efficacy and safety of lixisenatide once daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M) Diabetes Care 2013 [Epub ahead of print]
2. V.R. Aroda, and R. Ratner The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review Diabetes/Metabolism Research and Reviews 27 2011 528 542
3. A. Barnett Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes Core Evidence 6 2011 67 79
4. G. Bolli, M. Munteanu, S. Dotsenko, E. Niemoeller, G. Boka, and Y. Wu et al. Efficacy and safety of lixisenatide once-daily versus placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1) Diabetic Medicine 2013 (in press)
5. J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, and J.H. Brett et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) The Lancet 374 2009 39 47
6. J. de Heer, C. Rasmussen, D.H. Coy, and J.J. Holst Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas Diabetologia 51 2008 2263 2270
7. L. Distiller, and P. Ruus Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients Diabetes Care 57 Suppl 1 2008 A154
8. A. Flint, A. Raben, A. Astrup, and J.J. Holst Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans The Journal of Clinical Investigation 101 1998 515 520
9. V.A. Fonseca, R. Alvarado-Ruiz, D. Raccah, G. Boka, P. Miossec, and J.E. Gerich et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) Diabetes Care 35 2012 1225 1231
10. O.H. Gilja, T. Hausken, I. Wilhelmsen, and A. Berstad Impaired accommodation of proximal stomach to a meal in functional dyspepsia Digestive Diseases and Sciences 41 1996 689 696
11. R. Goke, H.C. Fehmann, T. Linn, H. Schmidt, M. Krause, and J. Eng et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells The Journal of Biological Chemistry 268 1993 19650 19655
12. S. Gonlachanvit, C.W. Hsu, G.H. Boden, L.C. Knight, A.H. Maurer, and R.S. Fisher et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients Digestive Diseases and Sciences 48 2003 488 497
13. J.J. Holst The physiology of glucagon-like peptide 1 Physiological Reviews 87 2007 1409 1439
14. M. Horowitz, C.K. Rayner, and K.L. Jones Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes Advances in Therapy 30 2013 81 101
15. L.A. Houghton, N.W. Read, R. Heddle, M. Horowitz, P.J. Collins, and B. Chatterton et al. Relationship of the motor activity of the antrum, pylorus, and duodenum to gastric emptying of a solid-liquid mixed meal Gastroenterology 94 1988 1285 1291
16. N. Imeryuz, B.C. Yegen, A. Bozkurt, T. Coskun, M.L. Villanueva- Penacarrillo, and N.B. Ulusoy Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms The American Journal of Physiology 273 1997 G920 G927
17. J. Jelsing, N. Vrang, G. Hansen, K. Raun, M. Tang-Christensen, and L.B. Knudsen Liraglutide: Short-lived effect on gastric emptying - Long lasting effects on body weight Diabetes, Obesity & Metabolism 14 2012 531 538
18. C. Kapitza, T. Forst, H.-V. Coester, F. Poitiers, P. Ruus, and A. Hincelin-Méry Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin Diabetes, Obesity & Metabolism 15 2013 642 649
19. L.B. Knudsen, P.F. Nielsen, P.O. Huusfeldt, N.L. Johansen, K. Madsen, and F.Z. Pedersen et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration Journal of Medicinal Chemistry 43 2000 1664 1669
20. H. Linnebjerg, S. Park, P.A. Kothare, M.E. Trautmann, K. Mace, and M. Fineman et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes Regulatory Peptides 151 2008 123 129
21. M. Lorenz, C. Pfeiffer, A. Steinsträßer, R.H. Becker, H. Rütten, and P. Ruus et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia Regulatory Peptides 185C 2013 1 8
22. J. Malone, M. Trautmann, K. Wilhelm, K. Taylor, and D.M. Kendall Exenatide once weekly for the treatment of type 2 diabetes Expert Opinion on Investigational Drugs 18 2009 359 367
23. J.J. Meier, B. Gallwitz, S. Salmen, O. Goetze, J.J. Holst, and W.E. Schmidt et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes The Journal of Clinical Endocrinology and Metabolism 88 2003 2719 2725
24. J.J. Meier, G. Kemmeries, J.J. Holst, and M.A. Nauck Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects Diabetes 54 2005 2212 2218
25. M. Moore, U. Werner, M. Smith, T. Rodewald, and A. Cherrington Effect of the glucagon-like peptide-1 receptor agonist AVE0010 on postprandial hepatic glucose metabolism in the conscious dog Diabetologia 50 Supp 1 2007 Abstract 0584
26. E. Naslund, N. King, S. Mansten, N. Adner, J.J. Holst, and M. Gutniak et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects The British Journal of Nutrition 91 2004 439 446
27. M.A. Nauck, G. Kemmeries, J.J. Holst, and J.J. Meier Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans Diabetes 60 2011 1561 1565
28. M. Pinget, R. Goldenberg, E. Niemoeller, I. Muehlen-Bartmer, H. Guo, and R. Aronson Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P) Diabetes, Obesity & Metabolism 2013 [Epub ahead of print]
29. S. Quddusi, T.P. Vahl, K. Hanson, R.L. Prigeon, and D.A. D'Alessio Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans Diabetes Care 26 2003 791 798
30. D. Raccah Efficacy and safety of lixisenatide in the treatment of type 2 diabetes mellitus: A review of phase III clinical data Expert Review of Endocrinology and Metabolism 8 2013 105 121
31. R. Ratner, M. Hanefield, P. Shamanna, K.W. Min, G. Boka, and P. Miossec et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea ± metformin (GetGoal-S) Poster presented at 47th Annual Meeting of the European Association for the Study of Diabetes, 12-16 September, Lisbon, Portugal 2011 (Abstract 785)
32. M.C. Riddle, R. Aronson, P. Home, M. Marre, E. Niemoeller, and P. Miossec et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L) Diabetes Care 2013 [Epub ahead of print]
33. M.C. Riddle, T. Forst, R. Aronson, L. Sauque-Reyna, E. Souhami, and L. Ping et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) Diabetes Care 2013 [Epub ahead of print]
34. J. Rosenstock, D. Raccah, L. Koranyi, L. Maffei, G. Boka, and P. Miossec et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X) Diabetes Care 2013 [Epub ahead of print]
35. J. Schirra, P. Houck, U. Wank, R. Arnold, B. Goke, and M. Katschinski Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans Gut 46 2000 622 631
36. J. Schirra, P. Kuwert, U. Wank, P. Leicht, R. Arnold, and B. Goke et al. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men Proceedings of the Association of American Physicians 109 1997 84 97
37. Y. Seino, K.W. Min, E. Niemoeller, A. Takami, and Investigators EFC10887 GETGOAL-L Asia Study Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) Diabetes, Obesity & Metabolism 14 2012 910 917
38. C. Thorkildsen, S. Neve, B.D. Larsen, E. Meier, and J.S. Petersen Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice The Journal of Pharmacology and Experimental Therapeutics 307 2003 490 496
39. G. Tougas, M. Anvari, J. Dent, S. Somers, D. Richards, and G.W. Stevenson Relation of pyloric motility to pyloric opening and closure in healthy subjects Gut 33 1992 466 471
40. U. Werner, M. Gerlach, M. Hofmann, and A. Herling Treatment of obese Zucker diabetic fatty rats with novel GLP-1 receptor agonist AVE0010 improves oral glucose tolerance and glycaemic control without risk of hypoglycaemia Diabetologia 49 Suppl 1 2006 398 399 (Abstract 0656-P)
41. U. Werner, M. Gerlach, M. Hofmann, and A.W. Herling The GLP-1 receptor agonist AVE0010 abolishes OGTT-induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycaemia Poster presented at the 67th Scientific Session of the American Diabetes Association, June 22-26, Chicago, IL 2007 (Abstract 0486-P)
42. U. Werner, G. Haschke, A.W. Herling, and W. Kramer Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes Regulatory Peptides 164 2010 58 64
43. U. Werner, J. Kuhlmann-Gottke, H. Ruetten, H.-L. Schäfer, and A.W. Herling Comparison of the once-daily GLP-1R agonists lixisenatide and liraglutide on prandial carbohydrate utilization in animal models Poster presented at the International Diabetes Federation's 21st World Diabetes Congress, 5-8 December, Dubai, United Arab Emirates 2011 (Poster D-0737)